Wenqi Jiang, M.D. Professor of Medical Oncology,  Chief of the Department of Medical Oncology. Deputy director of  Cancer Center, Zhongshan University, 

Address:  
     Department of Medical Oncology,
      Cancer Center, Zhongshan University.
      651 Dongfeng East Road,
      Guangzhou 510060,
      P. R. China.

Phone:   8620-87765368  ext. 5350 /2828
Fax:       8620-87761547
E-mail:    wqjiang@yahoo.com  

      Dr. Jiang received his MD from Shanghai  Medical University in 1982 and his Master of Science in Oncology from Sun Yat-sen University of Medical Sciences in 1988. He completed his clinical training in Internal Medicine at the Shanghai Medical University and in Medical Oncology  in  the  Sun Yat-sen University of Medical Sciences. Then  he  joined the  research group of  Dr. Zhongzen Guan, where he played a major role in development and evaluation of new anti-cancer  drugs.
     For a number of years, Dr. Jiang research has been focused on the developing and evaluation of  new anti-cancer drugs. Dr. Jiang has been taking part in the research on developing some new  anti-cancer drugs  and has  conducted  several  phase I and phase II clinical trial of new anti-cancer  drugs produced by  both  domestic  and  oversea  pharmoceutical companies.
    During 1995-1997, Dr. Jiang studied clinical pharmocology in the University  of  Alabama  at  Birmingham  as  a  visiting  scholar and received  further clinical training in MD Anderson  Cancer Center .
    Currently Dr. Jiang is focusing on developing a new anti-cancer drugs which  can  induce the  difference and  promote the apoptosis of cancer cells, and has the function  to  reverse multi-drug  resistance. This drug is going to enter phase I clinical trial in China recently.

Main publications:
    1. pharmocokinetics and clinical study of Two-route-chemotherapy using high dose cisplatin  intrapleurally with thiasulfateintravenously. 
              Chinese Journal of Cancer, 1989, 4(2): 149-154
    2. Phase I and II clinical trial of carboplatin.
            Chinese Journal of Cancer, 1993, 6(3): 116-120
    3. The role of neupogen (rhG-CSF) in high dose chemotherapy. 
                 Chinese Journal of Cancer,  1993, 12(6):   176-182
    4. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implications in fluorouracil-based chemotherapy. 
              Clinical Cancer Research, 1997, 3(3): 395-399.